anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Respiratory viral infections are frequent causes of acute respiratory distress syndrome (ARDS), a disabling condition with a mortality of up to 46%. The pulmonary endothelium plays an important role in the development of ARDS as well as the pathogenesis of pulmonary fibrosis; however, the therapeutic potential to modulate endothelium-dependent signaling to prevent deleterious consequences has not been well explored. Here, we used a clinically relevant influenza A virus infection model, endothelial cell-specific transgenic gain-of-function and loss-of-function mice as well as pharmacologic approaches and in vitro modeling, to define the mechanism by which S1PR1 expression is dampened during influenza virus infection and determine whether therapeutic augmentation of S1PR1 has the potential to reduce long-term postviral fibrotic complications. We found that the influenza virus-induced inflammatory milieu promoted internalization of S1PR1, which was pharmacologically inhibited with paroxetine, an inhibitor of GRK2. Moreover, genetic overexpression or administration of paroxetine days after influenza virus infection was sufficient to reduce postviral pulmonary fibrosis. Taken together, our data suggest that endothelial S1PR1 signaling provides critical protection against long-term fibrotic complications after pulmonary viral infection. These findings support the development of antifibrotic strategies that augment S1PR1 expression in virus-induced ARDS to improve long-term patient outcomes.
The active control group will receive advice to be physically active that corresponds to the intervention group in time and effort, equivalent to 60 minutes for 2 days a week and a minimum of 10 minutes for 5 days a week. To compensate for the extra attention received by the intervention group by the instructor via tele-yoga group, the participants in the activecontrol group's patients will be dialed or have SMS contact (the participant chooses a type of contact) with a physiotherapist or nurse after 2, 4, 8 and 12 weeks.
Substances are separated by extraction with a two-phase system comprising two normally mutually miscible liquids and a solid soluble in one but insoluble in the other.  The mixture of substances to be separated may be dissolved in one of the phases which is then brought into contact with the other in counter-current flow.  The two phases may be produced independently.  According to a modification one of the substances to be separated may form one of the three constituents of the two-phase system.  According to a further modification the system may comprise three phases.  The examples describe the partial separation of ascorbic acid from glucose and saccharose using the system water-calcium chloride-acetone, iron chloride from aluminium chloride using water-sodium chloride-acetone, insulin from organic extracts using water-ammonium sulphate-acetone-petroleum ether (3 phases), lysine from arginine using water-ammonium sulphate-isopropyl alcohol, barbaloine and isobarbaloine using water-sodium chloride-acetone and glucose from saccharose using water-magnesium sulphate-propionic acid.
With increased legalization and medicalization of marijuana (MJ), there is an urgent need to understand the acute effects of use. One of the most consistently observed cognitive outcomes associated with MJ use is memory dysfunction, which may have a substantial impact on daily life in individuals using MJ for recreational or medicinal purposes. Notably, there are numerous preparations of MJ with varying proportions of cannabinoids, which may differ in behavioral and cognitive effects. For instance, there is emerging evidence that acute administration of delta-9-tetrahydrocannabinol (THC), the main psychoactive constituent of MJ, hinders memory and reduces prefrontal and hippocampal functional magnetic resonance imaging (fMRI) activation, but cannabidiol (CBD) may mitigate some of these impairments. Given the role of glutamate in learning and memory, the investigators suggest that these effects may be subserved, in part, by glutamatergic mechanisms. The investigators will use magnetic resonance spectroscopy (MRS) to non-invasively measure glutamate in order to explore the neurochemical underpinnings of memory-related fMRI response changes following acute administration of THC and CBD in a randomized, double-blind, placebo-controlled, cross-over design. A total of 9 healthy participants ages 18-40 will be enrolled. Participants will first undergo one screening visit (\~4 hours), comprising informed consent, assessment of health history, psychiatric diagnoses, cognitive function, and substance use history, and a structural MRI session. This will be followed by 3 separate MJ dose visits (\~4 hours each), at which participants will complete neuroimaging after administration of one of 3 preparations of vaporized MJ in a randomized, counterbalanced, double-blinded fashion: 1) high THC and no CBD (THC), 2) high THC and high CBD (THC+CBD), and 3) no THC and no CBD (placebo MJ). As in the investigator's ongoing studies, bulk MJ plant material will be provided by the National Institute on Drug Abuse. MJ dose visits will comprise MJ administration, blood collection, MRS/fMRI scan, subjective reports, and a brief cognitive assessment.
The disclosure belongs to the field of image segmentation in medical image processing and discloses a three-dimensional medical image segmentation method and system based on short-term and long-term memory self-attention models, in which the method can segment a target area image in the medical image, which includes the following. (1) A training set sample is established. (2) Processing is performed on the original three-dimensional medical image to be segmented to obtain a sample to be segmented. (3) A three-dimensional medical image segmentation network based on short-term and long-term memory self-attention is established and trained. (4) The sample to be segmented is input to the network, and then a segmentation result of the target area in the sample to be segmented is output. By combining CNN and Transformer, a new model for accurate real-time segmentation of the target area (such as a tumor) in the three-dimensional medical image is obtained.
Cohort C completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Steroids should be used with caution in the presence of glaucoma.

Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. In acute purulent conditions of the eye, steroids may mask infection or enhance existing infection.

Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution.

The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.
Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework. Individuals randomized to this condition will also receive a free gun (cable) lock for each of their personal firearms. This will control for whether the effect of the provision of gun locks is accounted for by the simultaneous use of lethal means counseling.
PURPOSE:To obtain an ultraviolet screen excellent in ultraviolet-screening effect, light resistance, etc., by coating a particulate pigment having specific properties with a layer of an insoluble cerium cympound and a layer of amorphous silica, and baking the coated pigment at a given temp. for a given time. CONSTITUTION:An aqueous solution of a cerium salt (e.g. cerium chloride) is added to an aqueous dispersion of a particulate pigment having a refractive index of 1.45-1.6 and an average particle diameter of 0.1-50mum and made of, e.g. natural silica, synthetic silica, or glass, while the dispersion is kept being heated. The pH of the mixture is regulated to about 7-9 to deposit an insoluble cerium compound on the pigment surfaces to thereby form a coating layer. The coated pigment is dispersed into water, and a silicate solution is added thereto with heating and stirring to deposit amorphous silica on the coated particle surfaces. This pigment is baked at 200-1,000 deg.C for 30min or longer to produce an ultraviolet screen, which is useful for use in the production of a plastic, fiber, coating composition, etc.
Keloid is a typical fibrotic and inflammatory skin disease with unclear mechanisms and few therapeutic targets. In this study, we found that BMP1 was significantly increased in a collagen high-expressing subtype of fibroblast by reanalyzing a public single-cell RNA-sequence data set of keloid. The number of BMP1-positive fibroblast cells was increased in keloid fibrotic loci. Increased levels of BMP1 were further validated in the skin tissues and fibroblasts from keloid patients. Additionally, a positive correlation between BMP1 and the Keloid Area and Severity Index was found in keloid patients. In vitro analysis revealed collagen production, the phosphorylation levels of p65, and the IL-1β secretion decreased in BMP1 interfered keloid fibroblasts. Besides, the knockdown of BMP1 inhibited the growth and migration of keloid fibroblast cells. Mechanistically, BMP1 inhibition downregulated the noncanonical TGF-β pathways, including p-p38 and p-ERK1/2 signaling. Furthermore, we found the delivery of BMP1 siRNAs could significantly alleviate keloid in human keloid-bearing nude mice. Collectively, our results indicated that BMP1 exhibited various pathogenic effects on keloids as promoting cell proliferation, migration, inflammation, and ECM deposition of fibroblast cells by regulating the noncanonical TGF-β/p38 MAPK, and TGF-β/ERK pathways. BMP1-lowing strategies may appear as a potential new therapeutic target for keloid.
OBJECTIVES: Increasing epidemiological and experimental evidence suggests that particle exposure is an environmental risk factor for chronic kidney disease (CKD). However, only a few case-control studies have investigated this association in an occupational setting. Hence, our objective was to investigate associations between particle exposure and CKD in a large cohort of Swedish construction workers.
METHODS: We performed a retrospective cohort study in the Swedish Construction Workers' Cohort, recruited 1971-1993 (n=286 089). A job-exposure matrix was used to identify workers exposed to nine different particulate exposures, which were combined into three main categories (inorganic dust and fumes, wood dust and fibres). Incident CKD and start of renal replacement therapy (RRT) were obtained from validated national registries until 2021 and analysed using adjusted Cox proportional hazards models.
RESULTS: Exposure to inorganic dust and fumes was associated with an increased risk of CKD and RRT during working age (adjusted HR for CKD at age <65 years 1.15, 95% CI 1.05 to 1.26). The elevated risk did not persist after retirement age. Exposure to cement dust, concrete dust and diesel exhaust was associated with CKD. Elevated HRs were also found for quartz dust and welding fumes.
CONCLUSIONS: Workers exposed to inorganic particles seem to be at elevated risk of CKD and RRT. Our results are in line with previous evidence of renal effects of ambient air pollution and warrant further efforts to reduce occupational and ambient particle exposure.
PURPOSE:To provide a sustained release agent for active component composed of an ester of an oxyalkylene derivative such as polyhydric alcohol having carboxyl group and an active component having hydroxyl group, soluble in water as well as organic solvents and usable in the form of solid as well as liquid. CONSTITUTION:The objective sustained release agent is composed of an ester of (A) an oxyalkylene derivative of a polyhydric alcohol or polybasic carboxylic acid having carboxyl group (e.g. the compound of formula I to V) and (B) an active component having hydroxyl group such as perfumery (e.g. phenetyl alcohol or geraniol). The active component is slowly released by the hydrolysis of the agent to keep the activity over a long period. Since the agent has polyoxyalkylene ether skeleton, it can be prepared in the form of solid or liquid and the solubility to various solvents can be controlled.
The following adverse reactions have been reported with unregulated dietary supplements containing DHEA. The identity, purity and strength of the product used was not always known. It is therefore not possible to establish a causal relation to prasterone exposure. 

Cardiovascular Effects: Benign premature atrial contractions and occasional premature ventricular contractions occurred in a 55-year-old man after administration of DHEA; DHEA was discontinued and arrhythmias controlled by beta-blockers. (Sahelian 1998) 

One case of hepatitis has been reported in a patient with high pre-treatment anti-nuclear antibody (ANA) titers; causality is uncertain. (Buster 1992) 

Manic reactions during DHEA use have been described. (Dean 2000; Pies 2000) Risk factors for development of mania / psychosis are considered to be higher doses, combined use with antidepressants, alcohol or benzodiazepines, young patients (20-30 years, with peak endogenous DHEA levels), and cytochrome P450 polymorphisms (poor metabolizers).
The invention relates to the field of medicinal chemistry, pharmacology and medicine and contains a description of pharmaceutical compositions and combination drugs based on secretion stimulators and protectors of incretin hormones for the treatment of metabolic diseases (including diabetes, obesity, metabolic syndrome, etc.). The essence of the invention is that the pharmaceutical composition or combination drug contains a tetrahydrobenzo[f][1,4]oxazepine derivative which is a non-steroidal agonist of TGR5 bile acid receptors, or one of the endogenous bile acids, which stimulate the secretion of incretin hormones, as well as one of the known DPP-IV protease inhibitors. The TGR5 agonists are administered orally; the endogenous bile acids are administered rectally in the form of a suppository or gel. The following may be used as DPP-IV protease inhibitors: Vildagliptin, Saxagliptin, Sitagliptin, Teneligliptin, Linagliptin, Dutogliptin, Alogliptin, Gemigliptin, Carmegliptin, etc. In addition, the invention contains a description of novel derivatives of tetrahydrobenzo[f][1,4]oxazepine which are non-steroidal agonists of TGR5 bile acid receptors, as well as methods for the production thereof. The invention provides more effective therapy as a result of the synergistic action of the components, wherein it is possible to treat diabetes, obesity and other metabolic diseases and the cardiovascular and renal complications thereof simultaneously.
The present invention relates to extracellular vesicles which are derived from immunoregulatory macrophage cells. The vesicles exert immunoregulatory, angiogenic and tissue regenerative properties and are thus useful for the treatment of different diseases and conditions. In a further aspect, the invention relates to a pharmaceutical composition comprising the extracellular vesicles of the invention. In a still further aspect, the invention relates to the use of the extracellular vesicles or a pharmaceutical composition comprising such vesicles in medicine. In a still further aspect, the invention relates to the use of the extracellular vesicles or a pharmaceutical composition comprising such vesicles for treating or preventing immunological and non-immunological diseases and conditions, including autoimmune diseases, inflammatory diseases, hypersensitivity reactions, transplant rejection and micro- or macroangiopathies of the lower limbs. The invention also provides a process for preparing the macrophage- derived extracellular vesicles from blood monocytes. Finally, the invention provides a process for preparing immunoregulatory T cells which makes use of the extracellular vesicles.
Liquid treating agent admitted at 24 is applied to granular material within drum 10. The drum contains a helical mixing and conveying device (not shown) which is rotatable by a reversible motor 14. In use the drum is swung about axis 12 and the direction of rotation of motor 14 and hence the device is reversed each time drum axis 13 passes through the horizontal, so that the material is always conveyed towards the higher end of the drum. The drum is evacuated through fitting 16, the material enters at 22 and the treated product is removed at 26. Products treated are exemplified as acetyl salicylic acid treated by hydroxypropylmethyl cellulose and talc in methylene chloride, sugar pellets treated with zein and talc in alcohol and tablets treated with hydroxypropylmethyl cellulose and talc in methylene chloride and acetone. <IMAGE>
This study, designed as a randomized controlled trial with a pretest-posttest design, was conducted between September 2022 and August 2023 at the Internal Medicine clinic of Kanuni Sultan Süleyman Training and Research Hospital, Istanbul Provincial Health Directorate. The participants were voluntary individuals who had been diagnosed with Type-II Diabetes Mellitus at least 6 months prior, had a BMI ≥ 25kg/m² (overweight or obese), HbA1c ≥ 6.5%, were following a diabetes-specific diet or using oral antidiabetics, and were neither Reiki practitioners nor instructors. Randomization was used to assign participants to either the Reiki group or the control group. During the pretest, participants were asked to complete the Personal Information Form, the Subjective Well-Being Scale (SWS), and the OXFORD Happiness Scale (OHS). Pre-intervention fasting and postprandial blood glucose levels, HbA1c percentage, body mass index, LDL-HDL/total cholesterol, triglyceride levels, and blood pressure measurements were obtained from the patients' records and documented.The Reiki group received 20 minutes of remote Reiki once a day for 4 consecutive days, while no intervention was applied to the control group. The Subjective Well-Being Scale and OXFORD Happiness Scale were reapplied to both groups at the first and second months following the intervention, and the metabolic values, along with these scales, were measured again in the third month.
Purpose: This study aimed to assess early outcomes of the single port (SP) robotic low anterior access (LAA) for all upper urinary tract surgeries. In addition, it aimed to explore the impact of clinical factors, notably Body Mass Index (BMI), on post-operative outcomes and length of hospital stay. Materials and Methods: Overall, 76 consecutive patients underwent SP robotic surgery with LAA involving all upper urinary tract pathologies, with data collected prospectively. Baseline characteristics, intra- and post-operative outcomes, pain levels, and opioid use were analyzed. Statistical methods, including logistic regression and locally weighted scatterplot smoothing analysis, were used to assess same-day discharge (SDD) predictors and the association between BMI and SDD probability. According to the Institutional Review Board (IRB) protocol, only data recorded in our electronic medical record system was included. Results: Ten different procedures were performed with LAA, with no need for conversion to open surgery and complication rates in line with the literature (30 days: 5%, 90 days: 6.6%). Notably, 77.6% of patients were discharged on the same day. A significant association was found between BMI and prolonged hospital stay, particularly in obese patients (BMI ≥30 kg/m2). Post-operative pain was generally low (median VAS: 4), with over 70% discharged without opioid prescriptions. Conclusions: The novel LAA is a versatile approach for various upper urinary tract surgeries, including in obese patients. While achieving satisfactory post-operative outcomes, increased BMI correlated with a reduced likelihood of SDD. Further studies, including larger cohorts and multicenter collaborations, are warranted to explore anesthesiologic management and validate these findings.
Lurasidone is an atypical antipsychotic drug used both on patients with schizophrenia or bipolar disorder. It improves patients' clinical symptoms through dopamine D2 and serotonin 5-HT2A receptor antagonism. However, the effect of antipsychotic drugs on cardiac functions is an important parameter for patient safety during the treatment process. Although the existing literature on the cardiac effects of lurasidone is limited, atypical antipsychotic are known to cause corrected QT interval prolongation, arrhythmias and suppression on cardiac functions. Studies show that these cardiac side effects are mostly related to clozapine which is a D2 and 5-HT2A antagonist such as lurasidone. Though not fully understood, it is thought that cardiac events due to antipsychotic drugs occur because of type 1 hypersensitivity and rising levels of pro-inflammatory cytokines. It might also be related to ischemia that free oxygen radicals initiate at the molecular level.

D2 receptors play a critical role in the regulation of heart rate and vascular tone. D2 receptor antagonism may increase the risk of hypertension by changing systemic vascular resistance and heart rate. In addition, inhibition of D2 receptors may lead to loss of the vasodilator effects of dopamine, leading to impaired cardiovascular homeostasis. Similarly 5-HT2A receptors have important effects of cardiac functions. 5-HT2A receptor antagonism, together with imbalances in serotonin levels, may increase heart rate and affect vascular tone, leading to vasoconstriction. It is possible that the increase in systemic vascular resistance and cardiac inotropy through receptor antagonism may cause deterioration in cardiac functions and should be considered in clinical follow-up.

There are a limited number of studies examining the potential effects of lurasidone on cardiac functions. For example, one study reported that lurasidone treatment did not cause a significant prolongation of the QTc interval, while another study reported that the overall cardiac safety profile of lurasidone use was quite favorable. However, more data are needed to compare cardiac side effects between lurasidone and other antipsychotics and how these effects should be managed in clinical practice. The aim of this study is to gain information about the possible cardiac effects of the lurasidone molecule by evaluating left ventricular systolic function with the help of periodic transthoracic echocardiography. In particular, clarifying the potential risks of lurasidone on cardiac health and the clinical significance of these risks is important both to increase patient safety and to optimize treatment processes.
Participants will receive oral lenvatinib at a starting dose of 8 or 12 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle. The starting dose of lenvatinib will be based on Baseline body weight. Participants weighing greater than or equal to 60 kilograms (kg) will receive 12 mg QD; participants weighing less than 60 kg will receive 8 mg QD.